MetaPhore Pharmaceuticals initiates Phase I clinical trial of enzyme mimetic compound for oncology
. St. Louis, MO, May 31, 2001--MetaPhore Pharmaceuticals, Inc. today announced that it has received FDA approval of its Investigational New Drug (IND) application to conduct clinical trials in the U.S. to evaluate M40403, one of its enzyme mimetic compounds. . . MetaPhore has initiated a Phase I study to test the safety and tolerability and to determine the pharmacokinetics of the compound in n...FDA awards grant to metaphore pharmaceuticals to study septic shock in humans
. . . . MetaPhore and Saint Louis University researchers aim to explain. perplexing blood pressure drop . . . St. Louis, MO, November 2, 2000 The Food and Drug Administration (FDA) has awarded a six-month $100,000 Small Business and Innovation Research (SBIR) grant to MetaPhore Pharmaceuticals to study the dramatic and perplexing blood pressure drop that occurs during septic shock and leads to...NIH awards grant to MetaPhore Pharmaceuticals to study novel pain treatments
. . .St. Louis, MO, September 18, 2000 - The National Institutes of Health (NIH) has awarded a six-month $290,000 Small Business and Innovation Research (SBIR) grant to MetaPhore Pharmaceuticals to study potential new treatments for managing both acute and chronic pain. . .The grant will allow St. Louis-based MetaPhore to proceed with studies on pain using the company's patented metal-based com...